These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

747 related articles for article (PubMed ID: 25168784)

  • 21. Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram.
    Chan A; Isbister GK; Kirkpatrick CM; Dufful SB
    QJM; 2007 Oct; 100(10):609-15. PubMed ID: 17881416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Citalopram, QTc Prolongation, and Torsades de Pointes.
    Tampi RR; Balderas M; Carter KV; Tampi DJ; Moca M; Knudsen A; May J
    Psychosomatics; 2015; 56(1):36-43. PubMed ID: 25619672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of QT/QTc prolongation among newer non-SSRI antidepressants.
    Jasiak NM; Bostwick JR
    Ann Pharmacother; 2014 Dec; 48(12):1620-8. PubMed ID: 25204465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.
    Tseng PT; Lee Y; Lin YE; Lin PY
    Gen Hosp Psychiatry; 2012; 34(2):210.e13-5. PubMed ID: 22133983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lengthening of QT interval by antipsychotic drugs].
    Haverkamp W; Deuschle M
    Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing QT interval prolongation and its associated risks with antipsychotics.
    Nielsen J; Graff C; Kanters JK; Toft E; Taylor D; Meyer JM
    CNS Drugs; 2011 Jun; 25(6):473-90. PubMed ID: 21649448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment.
    Tümüklü MN; Tümüklü MM; Nesterenko V; Jayathilake K; Beasley CM; Meltzer HY
    J Clin Psychopharmacol; 2019; 39(2):100-107. PubMed ID: 30707117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
    Glassman AH
    J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.
    Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
    Ther Adv Psychopharmacol; 2014 Jun; 4(3):130-8. PubMed ID: 25057346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
    Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
    Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case series of drug-induced long QT syndrome and Torsade de Pointes.
    Tong KL; Lau YS; Teo WS
    Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic drugs and QT interval prolongation.
    Zareba W; Lin DA
    Psychiatr Q; 2003; 74(3):291-306. PubMed ID: 12918603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Generation Antipsychotic Drugs and QTc Interval Prolongation.
    Vieweg WV
    Prim Care Companion J Clin Psychiatry; 2003 Oct; 5(5):205-215. PubMed ID: 15213787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
    Taylor D
    CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs.
    Hondeghem LM
    J Cardiovasc Electrophysiol; 2006 Mar; 17(3):337-40. PubMed ID: 16643415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medical toxicologists' practice patterns regarding drug-induced QT prolongation in overdose patients: a survey in the United States of America, Europe, and Asia Pacific region.
    Othong R; Devlin JJ; Kazzi ZN
    Clin Toxicol (Phila); 2015 May; 53(4):204-9. PubMed ID: 25706450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].
    Trojak B; Pinoit JM; André D; Bonin B; Gisselmann A
    Presse Med; 2006 Apr; 35(4 Pt 2):699-704. PubMed ID: 16614617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.